$31.48
+0.17 (+0.54%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where VTVT is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
14 interventional · 4 with posted results
Held by 8 tracked-famous managers (MILLENNIUM MANAGEMENT LLC, MARSHALL WACE, LLP, RENAISSANCE TECHNOLOGIES LLC, JANE STREET GROUP, LLC, TWO SIGMA INVESTMENTS, LP, +3 more) · FINRA short interest 1.5 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 DiabetesNCT06334133Change in incidence of Level 2 or Level 3 hypoglycemiaRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: Cadisegliatin 800 mg QD, Cadisegliatin 800 mg BID, Placebo | Diabetes Mellitus, Type 1 | 150 | Apr 2027 | ≤ 254 d | 2026-07-28 |
| Cadisegliatin as Adjunctive Therapy to Insulin in Participants With Type 1 Diabetes Who Are Using Hybrid Closed Loop (HCL) SystemsNCT07616206To assess the change in Time in Range (TIR)Randomized · Triple-masked · Treatment | Phase 2 | Not yet recruiting | Drug: Cadisegliatin 800 mg QD, Placebo | Type 1 Diabetes (T1D) | 40 | Apr 2027 | ≤ 254 d | 2026-06-01 |
| Study of Azeliragon in Patients With Mild Alzheimer's Disease and Impaired Glucose ToleranceNCT03980730results2022-01-21Part 1 : Change From Baseline in the Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-cog14) at Month 6Randomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: for business reasons | Drug: Azeliragon, Placebo | Alzheimer Disease | 43 | 2020-12-01actual | — | 2022-01-21 |
| Evaluation of TTP399 in Patients With Type 1 DiabetesNCT03335371results2023-07-03Percent Change From Baseline in Glycosylated Hemoglobin (HbA1c) at Week 12Randomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1/2 | Completed | Drug: TTP399, TTP399, Placebo Oral Tablet | Diabetes Mellitus, Type 1 | 115 | 2019-12-20actual | — | 2023-07-03 |
| Evaluation of the Efficacy and Safety of Azeliragon (TTP488) in Patients With Mild Alzheimer's DiseaseNCT02080364results2021-05-07Change From Baseline in Alzheimer's Disease Assessment Scale - Cognitive (ADAS-cog) Total ScoreRandomized · Quadruple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose. | Drug: Azeliragon, Placebo | Alzheimer's Disease | 880 | 2018-06-01actual | — | 2021-05-07 |
| 2-Year Extension Study of Azeliragon in Subjects With Alzheimer's Disease (STEADFAST Extension)NCT02916056results2021-06-01Number of Subjects With at Least One Treatment-Emergent Adverse EventOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: Not due to safety but due to a lack of efficacy at the 5 mg azeliragon dose. | Drug: Azeliragon 5mg | Alzheimer's Disease | 297 | 2018-06-01actual | — | 2021-06-01 |
| A Study to Evaluate Safety and Efficacy of TTP273 for 12 Weeks in Subjects With Type 2 DiabetesNCT02653599Change in HbA1c from baseline at 12 weeksRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TTP273, Placebo | Type 2 Diabetes Mellitus | 174 | Nov 2016actual | — | 2017-02-10 |
| Add Glucokinase Activator to Target A1cNCT02405260Change in HbA1c (Glycosylated haemoglobin)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TTP399 400 mg, TTP399 800 mg, Sitagliptin 100 mg, Placebo | Diabetes Mellitus, Type 2 | 190 | Jul 2016actual | — | 2017-02-10 |
| A Study to Evaluate Safety and Efficacy of TTP054 for 12 Weeks in Subjects With Type 2 DiabetesNCT01665352Change from baseline in HbA1c (%) as compared to placeboRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TTP054, Placebo | Type 2 Diabetes Mellitus | 186 | May 2013actual | — | 2017-02-10 |
| A Safety Study of TTP4000 in Subjects With Alzheimer's DiseaseNCT01548430Number of participant with adverse eventsRandomized · Double-masked | Phase 1 | Completed | Drug: TTP4000, Placebo | Alzheimer's Disease | 8 | Feb 2013actual | — | 2015-02-12 |
| A 6 Week Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of GK1-399 in Type 2 DiabetesNCT01474083Pharmacokinetic parameters of GK1-399 from plasma concentrationsRandomized · Quadruple-masked · Basic science | Phase 1/2 | Completed | Drug: GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), GK1-399 (formerly TTP399), Placebo | Type 2 Diabetes Mellitus | 248 | Aug 2012actual | — | 2013-09-13 |
| Left Ventricular Assist Device (LVAD) Specialized Centers of Clinically Orientated Research (SCCOR) Coagulation - Acute Intrinsic Pathway Antagonist (IPA)NCT00909298The level of thrombin generation markersRandomized · Double-masked · Prevention | Phase 2 | Terminated | Drug: TTP889, Placebo | Coagulation | 2 | Jun 2010actual | — | 2011-06-27 |
| Safety Study of the Inhibition of Agouti-related Protein (AgRP) for the Management of Obesity and Weight LossNCT00779519Participant Adverse EventsRandomized · Double-masked · Treatment | Phase 2 | Completed | Drug: TTP435, Placebo | Obesity | 100 | Dec 2009actual | — | 2011-06-27 |
| Factor IX Inhibition in Thrombosis Prevention (The FIXIT Trial)NCT00119457To evaluate the antithrombotic efficacy of TTP889, administered once daily for three weeks, in patients who have completed standard prophylactic treatment for deep vein thrombosis after hip fracture surgery.Randomized · Double-masked · Prevention | Phase 2 | Completed | Drug: TTP889 | Venous Thromboembolism, Embolism and Thrombosis, Hip Fractures | 300 | — | — | 2009-06-03 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19